TY - JOUR
T1 - Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?
AU - Dekkers, Nik
AU - Westerouen van Meeteren, Menso
AU - Wolterbeek, Ron
AU - Farina Sarasqueta, Arantza
AU - Laleman, Wim
AU - Inderson, Akin
AU - Desschans, Bruno
AU - van Hoek, Bart
AU - Sebib Korkmaz, Kerem
AU - Vermeire, Severine
AU - Maljaars, Jeroen
PY - 2020/5
Y1 - 2020/5
N2 - Background: Liver transplantation remains the only effective evidence based treatment for advanced primary sclerosing cholangitis. However, recurrence of disease occurs in approximately 18%. Aims: This study aimed to assess risk factors of recurrence of primary sclerosing cholangitis. Methods: A retrospective cohort study was performed on patients undergoing transplantation for recurrence of primary sclerosing cholangitis in two academic centers (Leuven, Belgium and Leiden, The Netherlands). Besides other risk factors, the degree of mucosal inflammation was assessed as a potential risk factor using histological Geboes scores. Results: 81 patients were included, of which 62 (76.5%) were diagnosed with ulcerative colitis. Seventeen patients (21.0%) developed rPSC during a median follow-up time of 5.2 years. In a subset of 42 patients no association was found between the degree of mucosal inflammation and recurrence, using both original Geboes scores and multiple cut-off points. In the total cohort, cytomegaloviremia post-transplantation (HR: 4.576, 95%CI 1.688–12.403) and younger receiver age at time of liver transplantation (HR: 0.934, 95%CI 0.881–0.990) were independently associated with an increased risk of recurrence of disease. Conclusion: This study found no association between the degree of mucosal inflammation and recurrence of primary sclerosing cholangitis. An association with recurrence was found for cytomegaloviremia post-liver transplantation and younger age at time of liver transplantation.
AB - Background: Liver transplantation remains the only effective evidence based treatment for advanced primary sclerosing cholangitis. However, recurrence of disease occurs in approximately 18%. Aims: This study aimed to assess risk factors of recurrence of primary sclerosing cholangitis. Methods: A retrospective cohort study was performed on patients undergoing transplantation for recurrence of primary sclerosing cholangitis in two academic centers (Leuven, Belgium and Leiden, The Netherlands). Besides other risk factors, the degree of mucosal inflammation was assessed as a potential risk factor using histological Geboes scores. Results: 81 patients were included, of which 62 (76.5%) were diagnosed with ulcerative colitis. Seventeen patients (21.0%) developed rPSC during a median follow-up time of 5.2 years. In a subset of 42 patients no association was found between the degree of mucosal inflammation and recurrence, using both original Geboes scores and multiple cut-off points. In the total cohort, cytomegaloviremia post-transplantation (HR: 4.576, 95%CI 1.688–12.403) and younger receiver age at time of liver transplantation (HR: 0.934, 95%CI 0.881–0.990) were independently associated with an increased risk of recurrence of disease. Conclusion: This study found no association between the degree of mucosal inflammation and recurrence of primary sclerosing cholangitis. An association with recurrence was found for cytomegaloviremia post-liver transplantation and younger age at time of liver transplantation.
KW - Geboes
KW - IBD
KW - Mucosal inflammation
KW - Risk factors
KW - rPSC
UR - http://www.scopus.com/inward/record.url?scp=85081005199&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.dld.2020.02.006
DO - https://doi.org/10.1016/j.dld.2020.02.006
M3 - Article
C2 - 32147286
SN - 1590-8658
VL - 52
SP - 528
EP - 533
JO - Digestive and liver disease
JF - Digestive and liver disease
IS - 5
ER -